AKBM: Strong growth in core segments, improved margins, and robust outlook despite tariff risks

About this update from Aker Biomarine Asa

Q2 and Q3 2025 saw double-digit revenue and EBITDA growth, led by Human Health Ingredients and Consumer Health Products, with improved margins and operational leverage. The company is addressing production challenges, expanding in Asia, and expects continued growth, while managing risks from tariffs and restructuring.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Aker Biomarine Asa